1Dawson TM,Dawson VL.Molecular pathways of neurodegeneration in Parkinson's disease.Science,2003,302:819-822.
2Chung KK,Dawson VL,Dawson TM.New insights into Parkinson's di-sease.J Neurol,2003,250:15-24.
3Mrsic-Pelcic J,Pelcic G,Vitezic D,et al.Hyperbaric oxygen treatment:the influence on the hippocampal superoxide dismutase and Na+,K+-ATPase activities in global cerebral ischemia-exposed rats.Neurochem Int,2004,44:29-38.
4Neretin VIa,Lobov MA,Kotov SV,et al.Hyperbaric oxygenation in the complex treatment of Parkinson disease.Zh Nevropatol Psikhiatr Im S S Korsakova,1989,89:38-40.
5Mogi M,Togari A,Tanaka K,et al.Increase in level of tumor necrosis factor (TNF)-α in 6-OHDA-lesioned striatum in rats without influence of systemic L-DOPA on TNF-α induction.Neurosci Lett,1999,268:101-104.
6Deniz K,Carl R,Anders B.Characterization of behavioral and neurodegenerative changes following partial lesions of the nigrostriatal dopamine system induced by intrastriatal 6-hydroxydopamine in the rat.Exp Neurol,1998,152:259-277.
7XU Y,SUN S,CAO X.The protective effect of glutathione on dopaminergic neurons. J Tongji Med Univ,2002,22:355-358.
8Hohhoff VA, Vieregge P, Kessler J, et al. Discordant twins with Parkinson's disease: positron emission tomography and early signs of impaired cognitive circuits[J]. Ann Neurol, 1994, 36(2) :176- 182.
9Yoshino H, Hattori Y, Imai H, et al. Sparteine oxidation by hepatic cytochrome P-450 in patients with Parkinson's disease[J]. Rinsho Shinkeigaku, 1993, 33(3):261- 265.
10Iacopino AM, Christakos S. Specific reduction of calcium-binding protein (28-kilodalton calbindin-D) gene expression in aging and neurodegenerative diseases[J]. Proc Natl Acad Sci USA, 1990, 87(11):4078-4082.
7Rinne UK,Laraen JP,Siden,et al.Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations[J].Neurology,1998,(51):1309-1314.
8Stocchi F,Olanow CW.Conlinuous dopaminergic stimulation in early and advanced Parkinson's disease[J].Neurology,2004,62:556-563.
9Hauser RA,Hubble JP,Truong DD,et al.Randomized trial of the adenosine A(2A)receptor antagonist istradefylline in advanced PD[J].Neurology,2003,61(3):297-303.
10Henehcliffe C, Schumaeher HC, Burgut FT. Recent advances in Parkinson' s disease therapy: use of monoamine oxidase inhibitors [ J ]. Expert Rev Neurother,2005 ,5 (6) : 811 - 821.
